Floatz logo

pds0101

Reproductive System Cancer

National Cancer Institute (NCI)UNKNOWNPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Reproductive System Cancer cohort.

Asset / SponsorPhaseRating
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap
National Cancer Institute (NCI)
Phase 1/2CCC
Prgn-2009
National Cancer Institute (NCI)
Phase 1/2CCC
Ibuprofen
National Cancer Institute (NCI)
Phase 1/2CCC
Diphenhydramine
National Cancer Institute (NCI)
Phase 1/2CCC
Epinephrine
National Cancer Institute (NCI)
Phase 1/2CCC
Dexasone
National Cancer Institute (NCI)
Phase 1/2CCC
Immunocytokine Nhs-Il12
National Cancer Institute (NCI)
Phase 1/2CC

Same molecule, other indications

pds0101 is also rated in:

anal carcinomaActive
B
Indicative · Phase 2
58 / 100
View asset →
cervical cancerActive
CCC
Indicative · Phase 2
55 / 100
View asset →
HIV infectious diseaseActive
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →